A share price of Precision Biosciences Inc [DTIL] is currently trading at $13.56, up 4.47%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DTIL shares have gain 13.38% over the last week, with a monthly amount drifted -26.94%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, March 2024, Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update. In a post published today on Yahoo Finance, – Initiated final IND/CTA enabling studies for lead in vivo gene editing program PBGENE-HBV; expect to submit IND and/or CTA in 2024.
From an analyst’s perspective:
Precision Biosciences Inc [NASDAQ: DTIL] stock has seen the most recent analyst activity on June 17, 2022, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $7. Previously, William Blair downgraded its rating to Mkt Perform on June 09, 2022. Goldman downgraded its rating to a Neutral and decreased its price target to $7 on April 03, 2020. Stifel initiated its recommendation with a Buy and recommended $21 as its price target on March 05, 2020. In a note dated August 09, 2019, BTIG Research initiated an Buy rating and provided a target price of $22 on this stock.
Precision Biosciences Inc experienced fluctuations in its stock price throughout the past year between $8.25 and $28.44. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Precision Biosciences Inc [NASDAQ: DTIL] shares were valued at $13.56 at the most recent close of the market. An investor can expect a potential drop of -92.63% based on the average DTIL price forecast.
Analyzing the DTIL fundamentals
Trailing Twelve Months sales for Precision Biosciences Inc [NASDAQ:DTIL] were 48.73M which represents -33.59% decline. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -1.33%, Pretax Profit Margin comes in at -1.48%, and Net Profit Margin reading is -1.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -1.95 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.13 points at the first support level, and at 12.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.89, and for the 2nd resistance point, it is at 14.23.
Precision Biosciences Inc [DTIL] reported earnings per share of -$4.06 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$2.05/share, meaning a difference of -$2.01 and a surprise factor of -98.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$2.1 per share as compared to estimates of -$4.87 per share, a difference of $2.77 representing a surprise of 56.90%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Precision Biosciences Inc [NASDAQ:DTIL] is 2.73. Further, the Quick Ratio stands at 2.73, while the Cash Ratio is 2.41. Considering the valuation of this stock, the price to sales ratio is 1.13, the price to book ratio is 2.99.
Transactions by insiders
Recent insider trading involved SMITH J. JEFFERSON, Chief Research Officer, that happened on Jan 23 ’24 when 28000.0 shares were sold. President and CEO, Amoroso Michael completed a deal on Jan 22 ’24 to sell 0.14 million shares. Meanwhile, Chief Medical Officer List Alan sold 21526.0 shares on Jan 22 ’24.
